$0.68
2.26% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US4268971045
Symbol
HEPA
Sector
Industry

Hepion Pharmaceuticals Inc Stock price

$0.68
+0.11 19.47% 1M
-0.47 40.87% 6M
-2.56 79.01% YTD
-2.21 76.48% 1Y
-28.72 97.69% 3Y
-52.72 98.73% 5Y
-14,559.32 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.02 2.26%
ISIN
US4268971045
Symbol
HEPA
Sector
Industry

Key metrics

Market capitalization $3.86m
Enterprise Value $3.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.07
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-31.57m
Free Cash Flow (TTM) Free Cash Flow $-34.78m
Cash position $2.12m
EPS (TTM) EPS $-6.41
Short interest 1.13%
Show more

Is Hepion Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Hepion Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:

Hold
100%

Financial data from Hepion Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.06 0.06
14% 14%
-
-0.06 -0.06
14% 14%
-
- Selling and Administrative Expenses 7.81 7.81
10% 10%
-
- Research and Development Expense 24 24
32% 32%
-
-32 -32
28% 28%
-
- Depreciation and Amortization 0.06 0.06
14% 14%
-
EBIT (Operating Income) EBIT -32 -32
28% 28%
-
Net Profit -28 -28
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hepion Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hepion Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 months ago
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson's Disease (“PD”) and Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (“Hepion”), a clinical stage biopharmaceutical company that has been developing a treatment ...

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Head office United States
CEO John Brancaccio
Employees 22
Founded 2013
Website www.hepionpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today